Development of a human iPSC line (SMBCi004-A) from a patient with Gaucher disease

Zhao, Qingyang; Cui, Yazhou; Wang, Jing; Shi, Liang; Qi, Zijuan; Luan, Jing; Zhang, Yuang; Zhou, Xiaoyan; Han, Jinxiang

doi:10.1016/j.scr.2020.101989

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhao et al developed a human iPSC line (SMBCi004-A) from an 8-year-old female patient with Gaucher disease. As a gene therapy approach, some reprogramming factors, such as OCT4, SOX2, KLF4, and miR-302–367, were delivered using a non-integrative plasmid and the results showed complete pluripotency, normal genetic stability, and the ability to differentiate into three germ layers [ 64 ]. Moreover, Diaz-Font et al used an siRNA for the inhibition of the GCS gene as a potential therapeutic strategy for GD [ 65 ].…”

Section: Gaucher Diseasementioning

confidence: 99%

Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders

et al. 2022

View full text Add to dashboard Cite

The majority of monogenic liver diseases are autosomal recessive disorders, with few being sex-related or co-dominant. Although orthotopic liver transplantation (LT) is currently the sole therapeutic option for end-stage patients, such an invasive surgical approach is severely restricted by the lack of donors and post-transplant complications, mainly associated with life-long immunosuppressive regimens. Therefore, the last decade has witnessed efforts for innovative cellular or gene-based therapeutic strategies. Gene therapy is a promising approach for treatment of many hereditary disorders, such as monogenic inborn errors. The liver is an organ characterized by unique features, making it an attractive target for in vivo and ex vivo gene transfer. The current genetic approaches for hereditary liver diseases are mediated by viral or non-viral vectors, with promising results generated by gene-editing tools, such as CRISPR-Cas9 technology. Despite massive progress in experimental gene-correction technologies, limitations in validated approaches for monogenic liver disorders have encouraged researchers to refine promising gene therapy protocols. Herein, we highlighted the most common monogenetic liver disorders, followed by proposed genetic engineering approaches, offered as promising therapeutic modalities.

show abstract

Section: Gaucher Diseasementioning

confidence: 99%